Art. 2 Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination o…

Definitions

In forcesince 1 Jan 2025cited 16×

For the purposes of this Regulation, the definitions in Article 1 of Directive 2001/83/EC shall apply.

The following definitions shall also apply:

1.

‘Variation to the terms of a marketing authorisation’ or ‘variation’ means any amendment to:

(a)

the information referred to in Articles 12(3) to 14 of Directive 2001/82/EC and Annex I thereto, Articles 8(3) to 11 of Directive 2001/83/EC and Annex I thereto, Articles 6(2) and 31(2) of Regulation (EC) No 726/2004, or Article 7 of Regulation (EC) No 1394/2007;

(b)

the terms of the decision granting the marketing authorisation for a medicinal product for human use, including the summary of the product characteristics and any conditions, obligations, or restrictions affecting the marketing authorisation, or changes to the labelling or the package leaflet connected with changes to the summary of the product characteristics;

(c)

the terms of the decision granting the marketing authorisation for a veterinary medicinal product, including the summary of the product characteristics and any conditions, obligations, or restrictions affecting the marketing authorisation, or changes to the labelling or the package leaflet.

2.

‘Minor variation of type IA’ means a variation which has only a minimal impact, or no impact at all, on the quality, safety or efficacy of the medicinal product concerned;

3.

‘Major variation of type II’ means a variation which is not an extension and which may have a significant impact on the quality, safety or efficacy of the medicinal product concerned;

4.

‘Extension of a marketing authorisation’ or ‘extension’ means a variation which is listed in Annex I and fulfils the conditions laid down therein;

5.

‘Minor variation of type IB’ means a variation which is neither a minor variation of type IA nor a major variation of type II nor an extension;

6.

‘Member State concerned’ means a Member State whose competent authority has granted a marketing authorisation for the medicinal product in question;

6a.

‘Reference authority’ means:

(a)

the Agency where at least one of the marketing authorisations concerned is a centralised marketing authorisation;

(b)

the competent authority of the Member State chosen by the holder and accepted by that competent authority, or chosen by the coordination group referred to in Article 27 of Directive 2001/83/EC if none of the competent authorities of the Member States agrees to act as the reference authority, in the other cases;

7.

‘Relevant authority’ means:

(a)

the competent authority of each Member State concerned;

(b)

in the case of centralised marketing authorisations, the Agency;

8.

‘Urgent safety restriction’ means an interim change in the terms of the marketing authorisation due to new information having a bearing on the safe use of the medicinal product;

9.

‘Purely national marketing authorisation’ means any marketing authorisation granted by a Member State in accordance with the acquis outside the mutual recognition or decentralised procedure and that has not been subject to a complete harmonisation following a referral procedure.

The 10 that are cited most themselves, of 16.

  • Code général des impôts1635bisaeLaw

    … Ne sont pas subordonnées au paiement du droit certaines modifications mineures de type I A mentionnées au 2 de l'article 2 du règlement (CE) n° 1234/2008 de la Commission du 24 novembre 2008 concernant l'examen des modifications des …

  • Code de la santé publiquer5121-26Law

    … relative à chaque substance active individuelle ; 3° Pour les demandes d'extensions telles que définies au 4° de l'article 2 du règlement (CE) n° 1234/2008 de la Commission du 28 novembre 2008 concernant l'examen des modifications …

  • Code général des impôts, annexe II326quaterLaw

    Les modifications mineures d'une autorisation de mise sur le marché de type IA définies au 2 de l'article 2 du règlement (CE) n° 1234/2008 de la Commission du 24 novembre 2008 concernant l'examen des modifications des termes d'une …

  • Commission Regulation (EU) No 712/2012 of 3 August 2012 amending Regulation (EC) No 1234…Lawamends

  • Code général des impôts, annexe III344undeciesaLaw

    … l'exonération prévue au 3° et 4° du I de l'article 1635 bis AE, et pour celles de type IB mentionnées au 5° de l'article 2 du règlement (CE) n° 1234/2008 de la Commission du 24 novembre 2008 | Quelle que soit la procédure : 2 500 …

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    Article 2 of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (OJ 2008 L …

    16 Mar 2023 · 62021CJ0438

  • Décret n° 2019-388 du 30 avril 2019 relatif aux modifications mineures de type IA des te…Law

    … autorisation de mise sur le marché de médicaments à usage humain et de médicaments vétérinaires, notamment ses articles 2 et 4 ; Vu les lignes directrices de la Commission européenne en date du 16 mai 2013 relatives aux …

  • Judgment of the Court (Third Chamber) of 1 October 2015. Agenzia Italiana del Farmaco (AIFA) and Ministero della Salute v Doc Generici srl.Decision

    Article 2 of Regulation No 1234/2008 provides as follows: ‘For the purposes of this Regulation, the following definitions shall apply: “Variation to the terms of a marketing authorisation” or “variation” means any amendment …

    1 Oct 2015 · 62014CJ0452

  • Diergeneesmiddelenregeling1Law

    … 1234/2008; p. kleine wijziging van de tweede categorie: kleine wijziging van type IB als bedoeld in artikel 2 van verordening (EG) nr. 1234/2008; q. ingrijpende wijziging: ingrijpende wijziging van type II als bedoeld in artikel 2 van en …

  • Regulation (EU) 2024/568Law

    … Une redevance de 163200 EUR s’applique aux demandes de modification majeure de type II au sens de l’article 2, point 3), du règlement (CE) no 1234/2008 en vue de l’ajout d’une nouvelle indication thérapeutique ou de la …